These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

795 related articles for article (PubMed ID: 15654790)

  • 21. Efficacy of ramosetron in the treatment of male patients with irritable bowel syndrome with diarrhea: a multicenter, randomized clinical trial, compared with mebeverine.
    Lee KJ; Kim NY; Kwon JK; Huh KC; Lee OY; Lee JS; Choi SC; Sohn CI; Myung SJ; Park HJ; Choi MK; Bak YT; Rhee PL
    Neurogastroenterol Motil; 2011 Dec; 23(12):1098-104. PubMed ID: 21920001
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Randomised clinical trial: the clinical effects of a novel neurokinin receptor antagonist, DNK333, in women with diarrhoea-predominant irritable bowel syndrome.
    Zakko S; Barton G; Weber E; Dunger-Baldauf C; Rühl A
    Aliment Pharmacol Ther; 2011 Jun; 33(12):1311-21. PubMed ID: 21507028
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial.
    Camilleri M; Northcutt AR; Kong S; Dukes GE; McSorley D; Mangel AW
    Lancet; 2000 Mar; 355(9209):1035-40. PubMed ID: 10744088
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Eluxadoline benefits patients with irritable bowel syndrome with diarrhea in a phase 2 study.
    Dove LS; Lembo A; Randall CW; Fogel R; Andrae D; Davenport JM; McIntyre G; Almenoff JS; Covington PS
    Gastroenterology; 2013 Aug; 145(2):329-38.e1. PubMed ID: 23583433
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of pharmacological therapies in patients with IBS with diarrhoea or mixed stool pattern: systematic review and network meta-analysis.
    Black CJ; Burr NE; Camilleri M; Earnest DL; Quigley EM; Moayyedi P; Houghton LA; Ford AC
    Gut; 2020 Jan; 69(1):74-82. PubMed ID: 30996042
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical trial: the efficacy of alverine citrate/simeticone combination on abdominal pain/discomfort in irritable bowel syndrome--a randomized, double-blind, placebo-controlled study.
    Wittmann T; Paradowski L; Ducrotté P; Bueno L; Andro Delestrain MC
    Aliment Pharmacol Ther; 2010 Mar; 31(6):615-24. PubMed ID: 20003095
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Randomised clinical trial: alosetron improves quality of life and reduces restriction of daily activities in women with severe diarrhoea-predominant IBS.
    Cremonini F; Nicandro JP; Atkinson V; Shringarpure R; Chuang E; Lembo A
    Aliment Pharmacol Ther; 2012 Sep; 36(5):437-48. PubMed ID: 22779693
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [A randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of tegaserod in Chinese patients with constipation-predominant irritable bowel syndrome].
    Tegaserod Clinical Research Group
    Zhonghua Nei Ke Za Zhi; 2003 Feb; 42(2):88-90. PubMed ID: 12783702
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of diarrhea-predominant irritable bowel syndrome with traditional Chinese herbal medicine: a randomized placebo-controlled trial.
    Leung WK; Wu JC; Liang SM; Chan LS; Chan FK; Xie H; Fung SS; Hui AJ; Wong VW; Che CT; Sung JJ
    Am J Gastroenterol; 2006 Jul; 101(7):1574-80. PubMed ID: 16863563
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of combination therapy with probiotics and mosapride in patients with IBS without diarrhea: a randomized, double-blind, placebo-controlled, multicenter, phase II trial.
    Choi CH; Kwon JG; Kim SK; Myung SJ; Park KS; Sohn CI; Rhee PL; Lee KJ; Lee OY; Jung HK; Jee SR; Jeen YT; Choi MG; Choi SC; Huh KC; Park H
    Neurogastroenterol Motil; 2015 May; 27(5):705-16. PubMed ID: 25809913
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of treatment continuation with alosetron by IBS-D severity criteria.
    Nicandro JP; Shin P; Chuang E
    Curr Med Res Opin; 2012 Mar; 28(3):449-56. PubMed ID: 22313141
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist.
    Camilleri M; Mayer EA; Drossman DA; Heath A; Dukes GE; McSorley D; Kong S; Mangel AW; Northcutt AR
    Aliment Pharmacol Ther; 1999 Sep; 13(9):1149-59. PubMed ID: 10468696
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Importance of diarrhea in evaluating constipation in irritable bowel syndrome clinical studies.
    Basseri RJ; Kunkel D; Low K; Conklin JL; Pimentel M
    J Clin Gastroenterol; 2011 Oct; 45(9):790-3. PubMed ID: 21301356
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Antagonists of the type 3 serotonin receptor (5 -HT3) in IBS].
    Komoto S; Miura S
    Nihon Rinsho; 2006 Aug; 64(8):1487-90. PubMed ID: 16898618
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A double blind randomized controlled trial of a probiotic combination in 100 patients with irritable bowel syndrome.
    Drouault-Holowacz S; Bieuvelet S; Burckel A; Cazaubiel M; Dray X; Marteau P
    Gastroenterol Clin Biol; 2008 Feb; 32(2):147-52. PubMed ID: 18387426
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rifaximin and eluxadoline - newly approved treatments for diarrhea-predominant irritable bowel syndrome: what is their role in clinical practice alongside alosetron?
    Cash BD; Lacy BE; Rao T; Earnest DL
    Expert Opin Pharmacother; 2016; 17(3):311-22. PubMed ID: 26559529
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rifaximin therapy for patients with irritable bowel syndrome without constipation.
    Pimentel M; Lembo A; Chey WD; Zakko S; Ringel Y; Yu J; Mareya SM; Shaw AL; Bortey E; Forbes WP;
    N Engl J Med; 2011 Jan; 364(1):22-32. PubMed ID: 21208106
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A randomised controlled trial assessing the efficacy and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipation.
    Tack J; Müller-Lissner S; Bytzer P; Corinaldesi R; Chang L; Viegas A; Schnekenbuehl S; Dunger-Baldauf C; Rueegg P
    Gut; 2005 Dec; 54(12):1707-13. PubMed ID: 16020489
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and mode of action of mesalazine in the treatment of diarrhoea-predominant irritable bowel syndrome (IBS-D): study protocol for a randomised controlled trial.
    Leighton MP; Lam C; Mehta S; Spiller RC
    Trials; 2013 Jan; 14():10. PubMed ID: 23302220
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ischemic colitis and complications of constipation associated with the use of alosetron under a risk management plan: clinical characteristics, outcomes, and incidences.
    Chang L; Tong K; Ameen V
    Am J Gastroenterol; 2010 Apr; 105(4):866-75. PubMed ID: 20197759
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 40.